Press "Enter" to skip to content

Health Minister: Sputnik vaccine coming in May

last minute “data-mce-href =” “> Breaking news!

The Coronavirus Scientific Board convened with the vaccination agenda. Health Minister Fahrettin Koca made a press release after the meeting. Fahrettin Koca announced that with the agreement made, 50 million Sputnik V vaccine will come to Turkey in the next six months. Accordingly, the first shipment will be made in May.

Highlights from Fahrettin Koca’s speech:

Together with the whole world, we paid a heavy price during the epidemic.
We have experienced a harsh and unprepared transition period to a new World order. We experienced the pain of transition to a new order in every field, from the way of doing business to the way we touch our loved ones. We lost our loved ones. We took the risk not to see them in order to protect our loved ones.

This very grueling process took longer than expected. We tightened the restrictions once again to stop the increase in the number of cases and losses in our country. I hope this price we have paid will help us get rid of this epidemic completely.

Whether constraints work or are completely out of our lives is about how much we’ll fit into them. If we want to get rid of these constraints and disease at once, we must comply with the precautions and restrictions altogether. I am aware of what a difficult demand this is. It will not be easy to return to our old days without obtaining social immunity with the vaccination program. What we need to do to shorten this process is to comply with the restrictions and measures.


Vaccine supply is getting harder for the next 2 months, but it is expected that there will be an abundance of vaccines afterwards. The number of vaccine producers is increasing day by day. The production capacity of the vaccines produced is also increasing. As you know, two vaccines have been used in our country. Third, the final stage has been reached for the emergency approval of the Sputnik V vaccine, and an agreement has been made for the procurement of the vaccine. Turkey signed an agreement to receive 50 million doses of Sputnik V vaccine within 6 months. The first shipment will take place in May. In addition, technology transfer will be made for the production of this vaccine in our country.


By June, the delivered amount of Biontech vaccine will exceed 30 million doses. At the Scientific Committee meeting we held today, Prof. Dr. Taking the opinion of our teacher Uğur Şahin, it was decided to apply the time between the administration of two doses of Biontech vaccine as 6-8 weeks.

For Sinovac, although the shipment slows down from time to time, the amount of dose we receive will increase with the increased capacity. In addition, negotiations continue with other vaccine producers on the basis of agreement and early delivery.


Our local power, our local vaccines are getting ready to go to the field.

Our local inactive vaccine has completed Phase II trials. Preparations for the Phase III trials will begin in the next few days following the evaluation of the results. This is the last step before common use.

Our second inactive vaccine has started Phase I at Ankara City Hospital Clinical Research Center and has completed the vaccination of its first volunteers.

Another vaccine candidate, the virus-like particle vaccine, whose phase I study is ongoing, has vaccinated all of its first volunteers. It is aimed to start Phase II study at the end of May.

For our intranasal vaccine candidate, a research product was produced for Phase I study. Phase I study will begin after the necessary tests are completed.

Our Adenovirus-based Vector vaccine candidate has been produced and has reached the Phase I stage.


There is another issue that closely concerns the effectiveness of vaccine studies and the course of the epidemic: Mutations.

Mutations were expected for rNA viruses. This is what makes it difficult to fight the virus. There are dozens of mutation / variant types encountered around the world today. Some of these become dominant and spread rapidly, while some show limited spread.

Even if the virus changes itself and enters new forms extends its life, it has an end. These mutations will limit the virus’s ability to infect. Currently, the most common mutation type in our country is the UK variant. In addition, Brazilian and South African variants have also been seen. Finally, the Indian variant was also observed in 5 of our citizens in Istanbul. This variant was seen for the first time in our country and cases are followed up in isolation.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *